Reverb Therapeutics and Royalmount Join Forces for Lead Drug Development

• Reverb Therapeutics partners with Royalmount Laboratories to advance pre-IND work on its first drug candidate.

• The collaboration supports toxicity studies, scale-up manufacturing, and CMC tasks ahead of clinical trials.

Reverb Therapeutics has announced a collaboration with Montreal-based Royalmount Laboratories to support pre-IND enabling work on Reverb’s lead drug candidate, which is currently moving towards lead selection. The partnership will focus on critical bioanalytical and development tasks to prepare for anticipated clinical trials in approximately 18 months.

The collaboration leverages Royalmount’s expertise as a contract research organisation (CRO), helping biopharma clients advance discovery, preclinical, and clinical programs. Under the agreement, Royalmount will provide Reverb with resources for toxicity studies, manufacturing scale-up, and other CMC (Chemistry, Manufacturing, and Controls) activities.

“As we move towards the start of clinical trials in about 18 months’ time, we needed a scientific partner that could assist with toxicity studies, scale-up of manufacturing, and a variety of CMC tasks to ensure that our drug candidate moves swiftly from the lab to the clinic,” said David de Graaf, Ph.D., CEO of Reverb Therapeutics.

Royalmount Laboratories expressed enthusiasm about the collaboration. Adrien Musuku, Senior Director of Biopharmaceutics at Royalmount, noted, “Reverb Therapeutics is a perfect example of the kind of dynamic company we want to help advance to the clinic and beyond.”